Podiatrists in Itasca, IL Accepting Medicare

4 Podiatrists found. Showing 1 - 4

Marie Catherine Schlund, D.P.M. Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 209 N Walnut St, Itasca, IL 60143 Phone: 630-773-2478    Fax: 630-773-3695

Dr. Alexander Mckanna, DPM Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 209 N Walnut St, Itasca, IL 60143 Phone: 630-773-2478    Fax: 630-773-3695

M & M Foot And Ankle Specialists Llc Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 209 N Walnut St, Itasca, IL 60143 Phone: 630-822-2445

Itasca Foot And Ankle, Ltd. Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 209 N Walnut St, Itasca, IL 60143 Phone: 630-773-2478    Fax: 630-773-3695

News Archive

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

New MYiCLUBonline iPhone/iPad App from ABC Financial

ABC Financial, the leading software and payment processing provider to the health and fitness industry, announced today the release of their new MYiCLUBonline iPhone/iPad App.

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

FDA grants Orphan Drug Designation to Kamada's AAT product for type 1 diabetes

Kamada LTD., a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, was granted an Orphan Drug Designation for its Alpha-1 Antitrypsin (AAT) product to treat type 1 diabetes.

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

JANA Partners LLC today sent Charles River Laboratories International, Inc. a detailed critique of Charles River's revised investor presentation released earlier this week, in which Charles River once again seeks to persuade shareholders of the merits of its proposed acquisition of WuXi PharmaTech (Cayman) Inc..

Read more Medical News

› Verified 5 days ago